Study on patients with prostate cancer with the PET/MR

Phase 1

• Conditions: Patient diagnosed with prostatic carcinoma; MedDRA version: 21.1Level: LLTClassification code 10026389Term: Malignant neoplasm of prostateSystem Organ Class: 100000004864; Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2018-001034-18-IT
• Lead Sponsor: OSPEDALE SAN RAFFAELE

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-11-05
• Last Update Posted: 5 July 2021

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: Male
• Target Recruitment: 50

Inclusion Criteria

1. Age = 18 years
2. Diagnosis of prostate cancer proven by biopsy
3. Informed informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 25
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 25

Exclusion Criteria

1. Age less than 18 years
2. Inability to complete required imaging tests (eg severe claustrophobia)
3. Any other medical condition that may interfere with study compliance
4. All contraindications for MRI (eg pace-maker)
5. Evidence of metastatic disease to conventional imaging that would contraindicate the surgical procedure

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified